Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is repeated collapse or narrowing of the upper airway during sleep — most often at the level of the soft palate, tongue base, or lateral pharyngeal walls — causing apneas (near-complete cessation of airflow) or hypopneas (a marked reduction in airflow with a desaturation or arousal), while the chest and diaphragm continue, and often visibly intensify, their effort to breathe against the blocked airway. It is diagnosed using the apnea-hypopnea index (AHI): an AHI of 5 or more events per hour with associated symptoms (excessive daytime sleepiness, snoring, witnessed apneas) or relevant comorbidity (hypertension, coronary disease, stroke, atrial fibrillation, type 2 diabetes), or an AHI of 15 or more events per hour regardless of symptoms, establishes the diagnosis.^[1]

OSA is genuinely common and substantially underrecognized. A Canadian Thoracic Society/Canadian Sleep Society position paper cites unselected-population studies finding an AHI above 5 events/hour in roughly 24% of middle-aged men and 9% of middle-aged women, and a 2009 Public Health Agency of Canada survey in which 22% of adult Canadians (an estimated 5.4 million people) reported either being diagnosed with sleep apnea (3%) or being at high risk for it based on symptoms and risk factors (19%) — meaning the large majority of Canadians with clinically relevant OSA risk have never been formally diagnosed.^[2] That gap matters directly to a pharmacist: a patient requesting a sedative-hypnotic for "trouble sleeping," an opioid for chronic pain, or an OTC sleep aid at the counter may have unrecognized OSA driving the very symptom they are asking to have treated pharmacologically — and several of the most common answers to "help me sleep" or "manage this pain" (benzodiazepines, Z-drugs, opioids, sedating antihistamines) can worsen pharyngeal collapsibility and blunt the arousal response that normally terminates an obstructive event. See Pharmacologic Treatment Options and Drug Tables for the full caution framework.

Once OSA is diagnosed and CPAP is prescribed, the single biggest determinant of whether treatment actually works is not device selection — it is adherence, and adherence is disproportionately shaped by how well early side effects (mask leak, dryness, claustrophobia, pressure intolerance) are troubleshooted in the first few weeks.^[3] A pharmacist who can recognize a specific, fixable adherence barrier and either address it directly or route the patient back to their sleep/DME provider before they simply stop using the machine is intervening at the single highest-leverage point in this entire chapter.

Mechanism: a mechanically obstructed airway, not an absent respiratory drive

During sleep, pharyngeal dilator muscle tone (genioglossus and other upper-airway muscles) normally decreases, and lung volume falls — both of which reduce the airway's cross-sectional area and the longitudinal "tracheal traction" that helps keep it open. In OSA, an anatomically narrowed or more collapsible airway — from obesity-related peripharyngeal fat deposition, retrognathia, macroglossia, tonsillar hypertrophy, or simply an unfavourable craniofacial shape — cannot compensate for this normal sleep-related loss of tone and volume, and the airway partially or completely collapses. Critically, the brainstem's respiratory drive is intact and active throughout — the diaphragm and chest wall keep trying to move air, with effort that typically increases as the obstruction persists, until an arousal (often with a gasp or snort) restores airway patency. This is the opposite pattern from central sleep apnea, where airflow and respiratory effort go flat together because the brainstem has stopped signalling the chest to move at all — see that chapter for the full mechanistic contrast and its own distinct treatment framework. Mixed events, with an initial central component followed by an obstructive one, and coexisting OSA/CSA, are both real and are covered briefly in Special Populations.

Symptoms

• Loud, habitual snoring, often with witnessed pauses, gasping, snorting, or choking arousals reported by a bed partner — though the absence of a bed partner's report does not exclude OSA, and snoring can be softer or absent in some patients, particularly thinner patients and women.
• Excessive daytime sleepiness, unrefreshing sleep despite adequate time in bed, and morning headache.
• Nocturia, decreased libido, and, in some patients, mood symptoms or cognitive complaints (difficulty concentrating, memory complaints) that are sometimes misattributed to depression, aging, or an unrelated cause before OSA is considered.
• Treatment-resistant hypertension, new or worsening atrial fibrillation, or otherwise unexplained nocturnal or early-morning cardiovascular events — each a recognized association that should prompt OSA screening even without classic sleep complaints.

Severity is defined by the apnea-hypopnea index

Severity by itself does not fully predict symptom burden or treatment urgency — a patient with a moderate AHI and severe daytime sleepiness in a safety-critical occupation may need more urgent management than a patient with a higher AHI and minimal symptoms — but it is the standard framework used to grade disease and guide the treatment ladder in Choose Initial Treatment.^[1]

Key differential considerations

• Central sleep apnea — see that chapter; distinguished on polysomnography by absent, rather than persistent, respiratory effort during events. Chronic opioid therapy and heart failure with reduced ejection fraction are its 2 classic drivers, and either can coexist with anatomic OSA in the same patient.
• Obesity hypoventilation syndrome (OHS) — daytime hypercapnia (elevated PaCO₂) in a patient with obesity and sleep-disordered breathing; frequently coexists with severe OSA but reflects a distinct, more dangerous ventilatory failure pattern that changes monitoring and, often, the choice of PAP modality — see Special Populations.
• Insufficient sleep syndrome and poor sleep hygiene — genuinely common, and can coexist with mild OSA; treating only the OSA will not resolve daytime sleepiness that is actually driven by inadequate time in bed.
• Narcolepsy and other central disorders of hypersomnolence — consider when daytime sleepiness is disproportionate to OSA severity or persists despite confirmed adequate treatment; cataplexy, sleep paralysis, and hypnagogic hallucinations point away from OSA as the sole explanation.
• Medication- or substance-induced sedation — sedating antihistamines, benzodiazepines, opioids, alcohol, and some antidepressants can all produce daytime sleepiness independent of, or in addition to, OSA; see Pharmacologic Treatment Options and Drug Tables.

• Obesity, particularly central/neck adiposity — the single strongest modifiable risk factor, through peripharyngeal fat deposition narrowing the airway and reducing lung volume during sleep.
• Craniofacial and upper-airway anatomy — retrognathia/micrognathia, macroglossia, a high-arched or narrow palate, tonsillar or adenoidal hypertrophy, and a large neck circumference (STOP-Bang uses greater than 40 cm as its threshold criterion)^[4] all independently narrow or destabilize the airway, and can produce clinically significant OSA even in a patient who is not obese.
• Male sex — risk in women rises substantially after menopause, approaching male rates, likely reflecting loss of the relatively protective effect of progesterone/estrogen on upper-airway muscle tone and fat distribution.
• Older age, with prevalence rising through middle age and plateauing or slightly declining in the oldest adults.
• Family history and heritable craniofacial traits.
• Nasal obstruction — septal deviation, chronic rhinitis, or nasal polyps increase upper-airway resistance and can worsen OSA and reduce CPAP tolerance.
• Endocrine conditions — hypothyroidism (macroglossia, myopathy affecting airway muscles) and acromegaly (soft-tissue and craniofacial overgrowth) are recognized, reversible-in-part contributors worth screening for in an atypical presentation.
• Pregnancy, particularly the third trimester — weight gain, upper-airway mucosal edema, and reduced functional residual capacity all increase OSA risk, with associations to gestational hypertension/pre-eclampsia and gestational diabetes; see Special Populations.
• Fluid-retaining conditions — heart failure, chronic kidney disease, and venous insufficiency can worsen OSA through nocturnal rostral fluid shift into the neck and upper airway when supine.
• Down syndrome and other craniofacial syndromes — a recognized, high-prevalence association due to macroglossia, midface hypoplasia, and hypotonia.
• Smoking and evening alcohol use — smoking promotes upper-airway inflammation and edema; alcohol relaxes pharyngeal dilator muscle tone and blunts the arousal response, worsening both the frequency and severity of obstructive events, particularly in the first several hours of sleep.
• Sedative-hypnotic, opioid, and other CNS-depressant use — relevant both as a risk factor for unmasking or worsening OSA severity and as the direct subject of Pharmacologic Treatment Options and Drug Tables.

History and examination

Ask specifically about snoring loudness and pattern, witnessed apneas/gasping/choking, unrefreshing sleep, morning headache, and daytime sleepiness — quantified where possible with the Epworth Sleepiness Scale (0-24; a score of 10 or more suggests clinically significant sleepiness). Review comorbidities that raise pretest probability: hypertension (especially treatment-resistant), atrial fibrillation or other arrhythmia, coronary disease, stroke, type 2 diabetes, and heart failure. On examination, note BMI, neck circumference, tonsillar size, and craniofacial features (retrognathia, high-arched palate, macroglossia). Take a complete medication list, since sedative-hypnotics, opioids, and other CNS depressants both raise pretest suspicion and change the urgency of addressing the problem — see Pharmacologic Treatment Options.

STOP-Bang — the validated screening tool to use first

The STOP-Bang questionnaire, developed and validated at the University Health Network/University of Toronto, is an 8-item screening tool combining 4 symptom/history items (STOP) with 4 objective findings (BANG).^[4]

Interpretation: a total score of 0-2 suggests low risk of OSA; 3-4, intermediate risk; 5-8, high risk.^[4] A high or intermediate score does not itself diagnose OSA — it identifies who should be referred for objective testing, and a low score in a patient with a strong independent clinical suspicion (e.g., treatment-resistant hypertension, witnessed apneas) should not, by itself, be used to rule OSA out.

Objective testing — the only way to actually diagnose and grade OSA

Home sleep apnea testing (HSAT) is appropriate for adults with a high pretest probability of moderate-to-severe uncomplicated OSA and no significant comorbidity that would confound the result.^[1] Full, attended polysomnography (PSG) is preferred, rather than HSAT, when there is significant cardiopulmonary disease (including suspected heart failure-associated central sleep apnea), a neuromuscular disorder, suspected hypoventilation or opioid-associated central breathing disturbance, or when a technically inadequate or unexpectedly negative HSAT does not match a strong clinical suspicion.^[1][6] As in the Central Sleep Apnea chapter, most HSAT devices lack a true respiratory-effort channel, so they can quantify an AHI but generally cannot reliably distinguish obstructive from central events on their own — a relevant limitation when a mixed picture is suspected (chronic opioid therapy, known heart failure).

What the report should specify

• The overall AHI, and the proportion of events that are obstructive versus central versus mixed.
• Oxygen saturation nadir and total time spent below 90% saturation.
• Whether events cluster in the supine position (relevant to positional therapy — see Choose Initial Treatment) or in REM sleep.
• Any suggestion of hypoventilation (sustained oxygen desaturation without discrete events, or an elevated transcutaneous/end-tidal CO₂ where measured) that should prompt evaluation for obesity hypoventilation syndrome.

• Confirm the diagnosis objectively (STOP-Bang risk stratification followed by HSAT or PSG as appropriate) before committing a patient to long-term device therapy.
• Reduce the AHI to a clinically meaningful degree using a therapy the patient will actually use — adherence, not device selection alone, is the rate-limiting step for whether treatment works.
• Resolve or substantially improve daytime symptoms: excessive sleepiness, morning headache, and unrefreshing sleep.
• Support cardiometabolic risk reduction — blood pressure, glycemic control, and arrhythmia burden all plausibly benefit from effectively treated OSA, even though device therapy is not proven to be independently life-extending in every population.
• Achieve meaningful weight loss in patients with obesity-associated OSA — even a modest 5-10% body-weight reduction can meaningfully lower the AHI, and larger reductions can substantially reduce or occasionally resolve OSA.
• Systematically screen every new or renewed sedative-hypnotic, opioid, muscle-relaxant, or sedating OTC-sleep-aid request against the patient's known or suspected OSA and CPAP-adherence status before dispensing.
• Reinforce driving-safety and occupational-safety counselling in any symptomatic or newly diagnosed patient, and in any patient found to be CPAP-non-adherent, until effective treatment is re-established.
• Recognize CPAP intolerance as a solvable adherence problem in most cases, and escalate to oral appliance therapy, positional therapy, or surgical referral when troubleshooting genuinely fails, rather than writing the patient off as simply "non-compliant."

CPAP in use — the mask interface, humidified hose, and device display (here showing a pressure setting in cmH₂O) are exactly the concrete, fixable details a pharmacist can ask about when troubleshooting non-adherence. (MyUpchar, Wikimedia Commons, CC BY-SA 4.0)

Treatment ladder

• Weight loss — a structured behavioural program is first-line for every patient with overweight/obesity-associated OSA; even a modest 5-10% body-weight reduction meaningfully lowers the AHI, and bariatric surgery is a reasonable option for eligible patients with severe obesity. See Pharmacologic Treatment Options for adjunctive pharmacotherapy (tirzepatide/semaglutide) now specifically studied for AHI reduction in this population.^[9]
• CPAP — first-line device therapy for moderate-to-severe OSA and for symptomatic or comorbidity-associated OSA of any severity; see Choose Initial Treatment for the full adherence-support framework, which is the actual determinant of success.^[7][3]
• Oral appliance therapy — a reasonable alternative for mild-to-moderate OSA or documented CPAP intolerance, provided through dental sleep medicine, with efficacy confirmed by follow-up testing rather than assumed.^[8]
• Positional therapy — for patients whose events cluster in the supine position, as an adjunct or, in genuinely positional mild disease, a stand-alone option.
• Avoidance of alcohol and unnecessary sedating medication before bed — alcohol relaxes pharyngeal dilator tone and blunts the arousal response; see Pharmacologic Treatment Options and Drug Tables for the fuller prescribing-caution framework.
• Treatment of nasal obstruction (allergic rhinitis, septal deviation) — reduces upper-airway resistance and improves both OSA severity and CPAP tolerance.
• Oropharyngeal (myofunctional) exercises — a modest-evidence adjunct that can reduce AHI and snoring in some patients, generally as a complement to, not a replacement for, the therapies above.
• Surgical options (uvulopalatopharyngoplasty and related procedures, maxillomandibular advancement, hypoglossal nerve stimulation, bariatric surgery) — for selected patients after specialist assessment; see Choose Initial Treatment.
• Objective, device-download-based follow-up — confirming actual nightly use and residual AHI, not just asking how the patient feels, at every review; see Monitoring & Follow-Up.

Pregnancy

OSA risk rises through pregnancy, particularly the third trimester, from weight gain, upper-airway mucosal edema, and reduced functional residual capacity, and is associated with gestational hypertension/pre-eclampsia and gestational diabetes. STOP-Bang was not developed or validated in pregnant patients specifically, so clinical suspicion (snoring, witnessed apneas, excessive sleepiness, or new/worsening hypertension) should still prompt testing even with a reassuring score. CPAP is considered safe in pregnancy and remains first-line when OSA is diagnosed. GLP-1/dual-agonist pharmacotherapy for weight management (tirzepatide, semaglutide) is not appropriate in pregnancy — counsel patients to discontinue before a planned conception per the product monograph, and refer any weight-management goal during pregnancy itself to obstetric care. Sedative-hypnotic and opioid caution (see Pharmacologic Treatment Options) is especially relevant in pregnancy given the added maternal and fetal considerations.

Breastfeeding

CPAP use is fully compatible with breastfeeding. Data on solriamfetol, armodafinil, and modafinil in breastfeeding are limited; individualized specialist input is reasonable before starting any of them in a breastfeeding patient. Data on tirzepatide/semaglutide in breastfeeding are similarly limited — individualize.

Older adults

OSA prevalence rises with age, though the strength of its independent mortality association appears to attenuate somewhat in the oldest patients; treatment is still worthwhile for symptoms, quality of life, and cardiometabolic risk. Older adults are more susceptible to the sedation, cognitive impairment, and fall risk from any CNS-depressant medication layered onto OSA-related sleep fragmentation, and are more likely to be on polypharmacy that includes one or more agents from the Drug Tables caution list — apply an even lower threshold to flag combinations for prescriber review, and prefer non-pharmacologic approaches (including CBT-based strategies) over a new sedative-hypnotic for comorbid insomnia specifically because of this added risk.

Renal impairment

Solriamfetol requires dose reduction in moderate renal impairment and should be avoided in severe renal impairment/ESRD (see Pharmacologic Treatment Options). Gabapentin and pregabalin both require renal dose adjustment, which becomes doubly relevant when either is being used alongside an opioid in a patient with OSA (see Drug Tables). Several opioids also require renal-based adjustment — see each agent's own Drug Database entry.

Hepatic impairment

Armodafinil and modafinil dosing should be adjusted with caution in significant hepatic impairment per the product monograph. Several benzodiazepines and opioids have reduced or less predictable clearance in hepatic impairment — involve a pharmacist or specialist experienced with dosing in this setting rather than adjusting empirically.

Obesity hypoventilation syndrome overlap

An obese OSA patient with daytime hypercapnia needs closer monitoring than uncomplicated OSA — bilevel PAP is often preferred over straight CPAP, weight management is prioritized even more heavily, and supplemental oxygen should never be used alone, without PAP, given the risk of worsening hypercapnia in a patient whose ventilatory drive is already compromised.

Perioperative patients

Preoperative STOP-Bang screening identifies patients who need explicit anesthesia/surgical-team flagging regardless of formal OSA diagnosis status; known or high-risk OSA patients generally warrant opioid-sparing multimodal analgesia and closer postoperative respiratory monitoring (continuous pulse oximetry where available) when opioids or sedatives are used.^[5]

Patients on chronic opioid therapy

Do not assume a breathing disturbance in a patient on chronic opioids is purely obstructive — opioid-associated central and ataxic breathing patterns (see the Central Sleep Apnea chapter) are a real, dose-related, distinct phenomenon that can coexist with anatomic OSA. A mixed picture changes the workup (full PSG is generally needed to characterize it) and the treatment approach.

Commercial drivers and other safety-critical occupations

The CTS/CSS position paper found that severity of OSA alone is not a reliable predictor of collision risk and should not be used in isolation to judge fitness to drive; the decision to restrict driving rests with the licensing authority, informed by the treating clinician's assessment, documented CPAP compliance (for non-commercial drivers) or a more rigorous compliance assessment (for commercial drivers), and provincial guidance, which a pharmacist should be aware exists even though the formal determination is not a pharmacist's role.^[2] Reinforce that driving safety depends on demonstrated, objectively confirmed treatment adherence, not simply having a prescription for CPAP.

Arrange early CPAP follow-up (within the first 1 to 4 weeks) specifically to identify and troubleshoot adherence barriers before they become entrenched non-use, using the framework in Choose Initial Treatment.^[3] At every follow-up, review objective device-download data — hours of use per night, percentage of nights meeting the adherence threshold, mask-leak metrics, and residual AHI reported by the device — rather than relying on the patient's subjective sense of "it's going fine."

Symptom and outcome tracking

Track the Epworth Sleepiness Scale trend, resolution of morning headache and nocturia, and blood pressure over time alongside the device data. A normalized device-reported AHI without corresponding symptom improvement, or persistent sleepiness despite a genuinely low device-reported AHI and confirmed high adherence, both warrant reassessment rather than simply continuing the current plan unchanged — see Treatment Failure/Next Step.

Re-testing after significant change

Repeat objective testing, or at minimum a detailed device-download review, after any significant weight change, CPAP pressure adjustment, switch to oral appliance or positional therapy, or new use of a wake-promoting agent — confirming the breathing pattern and AHI have actually changed is part of monitoring, not an optional extra step.

Pharmacotherapy-specific monitoring

For solriamfetol, armodafinil, or modafinil: reconfirm adequate PAP/oral-appliance adherence at every renewal — these agents should never simply be continued as a substitute for fixing inadequate device therapy — and monitor blood pressure/heart rate (solriamfetol) or mood and sleep quality more broadly. For tirzepatide/semaglutide used adjunctively: standard GLP-1/dual-agonist monitoring (GI tolerability, gallbladder and pancreatitis symptoms, glycemic monitoring if diabetic) plus explicit reassessment of AHI and PAP pressure requirements as weight changes, since substantial weight loss can meaningfully reduce or occasionally resolve OSA.^[9]

Sedative-hypnotic, opioid, and muscle-relaxant renewals

Reassess a patient's OSA/CPAP-adherence status at every renewal of any agent on the Drug Tables caution list, not only at initial dispensing — a patient's adherence and risk profile can change over time even when the prescription itself has not.

Driving and occupational safety

Revisit driving-safety and occupational-safety counselling at every significant clinical change: a new diagnosis, discovered non-adherence, a medication change involving a sedating agent, or a new report of daytime sleepiness episodes while driving.^[2]

1. Persistent excessive daytime sleepiness despite objectively confirmed adequate CPAP adherence and an optimized pressure setting: first rule out other contributors (insufficient total sleep time, depression, another sleep disorder, a sedating medication) before adding a wake-promoting agent; if those are excluded, solriamfetol or armodafinil/modafinil are reasonable adjuncts.^[10][11]
2. CPAP non-adherence despite systematic troubleshooting (mask type/fit, humidification, desensitization, pressure mode): escalate to oral appliance therapy for mild-to-moderate disease, or reassess candidacy for positional therapy, further mask/pressure-mode trials, or surgical/hypoglossal-nerve-stimulation referral for appropriately selected moderate-to-severe patients.^[8]
3. Persistently elevated device-reported AHI despite reported consistent nightly use: reassess mask fit and leak specifically, consider a switch from fixed-pressure CPAP to auto-titrating PAP or a re-titration study, and evaluate for a coexisting or treatment-emergent central component (see the Central Sleep Apnea chapter) rather than assuming the device settings simply need to be increased.
4. Worsening symptoms or a rising AHI despite therapy that was previously effective: reassess for a new driver — weight gain, a newly started sedating or opioid medication, new heart failure, or a new central component — rather than intensifying the existing device settings without first identifying why control has changed.
5. Inadequate weight-loss response in obesity-associated OSA: revisit the structured behavioural program, consider adjunctive pharmacotherapy (tirzepatide/semaglutide) if not already used, or refer for bariatric surgery assessment in eligible patients with severe obesity.^[9]
6. Diagnostic uncertainty, or no meaningful response to any standard therapy: refer to sleep medicine for reassessment, considering overlap syndromes (obesity hypoventilation syndrome, COPD-OSA overlap) or an alternate diagnosis entirely rather than continuing empiric therapy indefinitely.
7. A patient repeatedly requesting a sedative-hypnotic, opioid dose increase, or OTC sedating sleep aid despite known untreated or non-adherent OSA: escalate to the prescriber, reinforce non-drug insomnia and pain-management strategies, and do not simply continue dispensing without that conversation happening.

• Ruling out OSA because a patient "doesn't snore loudly" — snoring can be soft or absent, particularly in thinner patients and women, and its absence should never be used alone to lower suspicion.
• Treating a STOP-Bang score, or symptom impression alone, as equivalent to an objective, AHI-based diagnosis — it is a screening tool for who needs testing, not a diagnostic test itself.^[4]
• Concluding CPAP "didn't work" after a single difficult night or week, without systematically troubleshooting mask fit, humidification, desensitization, and pressure mode first — most early CPAP abandonment is a fixable adherence problem, not a genuine treatment failure.^[3]
• Starting a wake-promoting agent (solriamfetol, armodafinil, modafinil) for daytime sleepiness without first objectively confirming adequate PAP/oral-appliance adherence — this can mask undertreated OSA rather than address its actual cause.^[7]
• Dispensing or renewing a sedative-hypnotic, opioid, or muscle relaxant to a patient with known untreated or non-adherent OSA without flagging it to the prescriber — the centrepiece prescribing-safety issue in this chapter; see Pharmacologic Treatment Options, Drug Tables, and Algorithm C.
• Recommending an OTC sedating antihistamine (e.g., a diphenhydramine-containing "PM" product) for sleep without first asking about snoring, witnessed apneas, or other OSA risk factors — a common, easy-to-miss counter-level blind spot.
• Missing obesity hypoventilation syndrome in a severely obese OSA patient with daytime hypercapnia signs, and managing it as if it were uncomplicated OSA.
• Failing to provide explicit driving-safety counselling to a newly diagnosed, symptomatic, or CPAP-non-adherent patient in a safety-critical occupation.^[2]
• Assuming positional therapy or an oral appliance is "good enough" for severe OSA with significant comorbidity without an objective efficacy check.
• Continuing supplemental oxygen alone, without PAP, as OSA therapy — oxygen alone does not correct the underlying obstruction or the arousal pattern, and can worsen hypercapnia in a patient with coexisting hypoventilation.

How to use this table: Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment where relevant. Select any drug name to open its complete Pharmasist Drug Database page. The third section of this table — sedatives, opioids, and muscle relaxants — is intentionally the most detailed section in this chapter, because screening these exact prescription and OTC categories against a patient's known or suspected OSA/CPAP-adherence status is one of the highest-yield, most concrete interventions a pharmacist can make for this condition. None of these agents are contraindicated outright in every OSA patient; the message is dose-conscious caution, avoiding unnecessary combinations (especially a benzodiazepine or Z-drug together with an opioid), and confirming CPAP adherence status before renewing — not blanket avoidance.

Pharmacotherapy for Residual Excessive Daytime Sleepiness Despite Adequate CPAP Use

Reserve for patients in whom objectively confirmed, adequate PAP or oral-appliance adherence has not resolved daytime sleepiness. Never a first step, and never a substitute for confirming adherence.

Adjunctive Pharmacotherapy for Weight Loss in Obesity-Associated OSA

Targets the obesity driver itself rather than the airway obstruction directly. Does not replace confirmed device therapy or objective AHI reassessment as weight changes.

Sedatives, Opioids, and Muscle Relaxants — Use With Caution or Avoid in Untreated or CPAP-Non-Adherent OSA

Each of these classes can worsen pharyngeal collapsibility, blunt the arousal response that normally terminates an obstructive event, or add respiratory-depressant burden on top of an already-obstructed airway. Screen every new prescription, refill, or OTC recommendation in this list against the patient's known or suspected OSA/CPAP-adherence status; escalate concerning combinations (especially a benzodiazepine or Z-drug together with an opioid) to the prescriber rather than dispensing without comment.